By proceeding, you agree to our Terms of Use and Privacy Policy.
At Promega Corporation, creativity and connection drive discovery and innovation. We celebrate scientific discovery and the creative application of science to solve problems.
22-24 February 2022
The Only Global RAS Dedicated Conference is Returning in 2022 with the 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit! Year on year, we are proud to unite the leading frontiers of the RAS industry to showcase expertise, technical data and pipeli
Event Ended
Virtual
Paid
26-28 April 2022
The 2nd Ligase Targeting Drug Development Summit returns with new insight and data from pioneers in the field to delve deep into ligase biology, assays to investigate functions as well as screening tools for optimum ligand identification and validati
Hybrid
Boston
10-12 May 2022
Welcome to the 2nd Induced Proximity-Based Drug Discovery Summit Coming to Boston this May, the 2nd Induced Proximity-Based Drug Discovery Summit is the only industry and academic dedicated summit focused on exciting innovations and emerging case stu
USA
26-29 July 2022
With a plethora of cytokine-based modalities and targets storming across biopharma, the complexities and interactions of cytokines involved in the immune system is an exciting opportunity for all. From understanding biology to discovering and combini
19-22 September 2022
Across 3 main conference days and 8 tracks, 200+ CAR and TCR experts will lead you and your peers in discussions from novel allogeneic approaches with enhanced safety considerations, the latest in vivo gene engineering techniques, and advances in CMC
26-28 September 2022
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging
29-30 September 2022
Gain valuable insights into the approaches impacting the immunotherapy field through 40+ outstanding presentations tackling key discussion points in immuno-oncology, immunology and inflammation.Benefits to Attending... Gain a forward-looking perspect
UK
London
11-12 October 2022
The field of protein degradation has accelerated, and substantial interest is owed to its promise to therapeutically degrade proteins proving intractable to classical small molecule inhibition. As the field patiently waits for clinical trial readouts
Switzerland
Basel
25-28 October 2022
The 5th Annual Targeted Protein Degradation Summit is the world leading industry-dedicated conference that spans the full drug development pipeline from discovery through to the clinic addressing key challenges to make this exciting new modality a th
14-16 November 2022
Network with more than 1,000 colleagues at PEGS Europe, the largest protein & antibody engineering event in Europe, which has been described as "the best biologics technology meeting in Europe.
Spain
Barcelona
28-01 December 2022
Develop, Validate & Implement Cell-Based & Biophysical Analytical Methods to Guarantee Safe, High Quality, Consistent & Efficacious Gene Therapy Products at Scale The past twelve months have culminated in an unprecedented level of excitement, investm
29-01 December 2022
Welcome to the 4th Inflammasome Therapeutics Summit The Only Meeting Uniting Industry & Academia to Progress Inflammasome-Centered Drug Development The 4th Inflammasome Therapeutics Summit returns to Boston, uniting industry pioneers during this exci
04-08 December 2022
THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS Brand New Session Themes for 2022: How to Develop an Antibody-based Drug from Discovery to IND? Adaptive Immune Receptor Repertoire Data Processi
San Diego
06-08 December 2022
Uniting Technical Personnel to Expand Assay Capabilities for Next Generation Protein Degraders Bringing together technical expertise sharing case studies with actionable insights, the Inaugural TPD Assay Development & Screening Summit has been establ
24-26 January 2023
Welcome to the 6th DDR Inhibitors Summit! DNA damage response inhibition has amassed a lot of interest over the last decade as it exposes a massive vulnerability in cancer cells. This has a huge potential to treat many types of tumors such as breast
Built with biopharmaceutical industry insights, this in-person meeting will bring together KOLs to delve deep into the key remaining challenges when it comes to identifying, designing and developing the next generation of molecular glues and truly un
The 6th DDR Inhibitors Summit 2023 is the premier event for pharmaceutical and biotech researchers to discuss advances, challenges, and new solutions in the field of DDR inhibitors.
Boston,
21-23 February 2023
Returning for the 2nd year, the GPCR-Targeted Drug Discovery Summit is the only industry-led meeting of its kind dedicated to congregating the most forward thinking biotechs, established large pharma, and key academic opinion leaders committed to dis
10-13 April 2023
Drug Discovery Chemistry is a dynamic conference for medicinal and biophysical chemists working in pharma, biotech, and academia. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting op
18-20 April 2023
The pharmaceutical industry is currently focused on developing biologic drugs that target the FcRn receptor pathway to treat autoimmune diseases, with companies such as Argenx, Janssen, UCB and Immunovant competing to tackle myasthenia gravis. The 3r
16-18 May 2023
Revolutionizing Drug Discovery & Development with Advanced 3D Models In light of recent advancements, including the FDA Modernization Act 2.0 signed by President Biden in December 2022, the successful IND approval for a Phase 2 clinical trial using o
31-02 June 2023
The 2nd Cell Therapy Potency Assay Summit aims to help experts improve their approach to potency assay development in order to align with clinical outcomes and regulatory guidelines. Over 100 professionals will gather to discuss how to design better
27-29 June 2023
The 4th Cytokine-Based Drug Development Summit presents an opportunity for cytokine drug developers to explore new possibilities in disease treatment within and beyond oncology. With promising masking and tissue targeting mechanisms and a wealth of p
25-27 July 2023
Whilst still in infancy, the rise of multispecific drugs that drive induced proximity between otherwise disparate biological targets is shifting the drug discovery paradigm towards therapeutic interventions for previously undrugged, or hard-to-drug t
29-01 September 2023
The Vice President of Discovery and Translational Research at Deverra Therapeutics, Erika von Euw, highly recommends attending the upcoming CAR-TCR Summit if you work in cell therapy. Last year marked a significant milestone in the field of cell ther
25-25 September 2023
The coronavirus pandemic ignited interest in learning more about immune responses to infections, their downstream effects, and how they can be modulated. It also gave rise to increased awareness of the role of immunity in diseases like cancer, neurod
Washington, DC
There has been growing interest in targeting kinases such as JAK, TYK, IRAK, SIK, CDK, MEK, ERK, RTK, PLK, PI3K, ALK, MAPK, GSK, LRRK, and more for their role in neurodegeneration, inflammation, cancer, autoimmune, and other disorders. However, targe
26-27 September 2023
Cambridge Healthtech Institute’s two-part conference on Artificial Intelligence (AI)/Machine Learning (ML)-Enabled Drug Discovery will highlight the increasing use of computational tools, AI modeling, algorithms, and data science for identifying nove
While finding novel druggable targets and drug modalities for therapeutic intervention remains a top priority for the pharma/biotech industry, identifying and validating "good" targets and leads remains challenging. Cambridge Healthtech Institute’s c
Cambridge Healthtech Institute's GPCR-Based Drug Discovery conference is now in its 18th year. G protein-coupled receptors (GPCRs), because of their central role in so many cellular processes, are still among the largest class of molecules modulated
Small molecule-based therapeutic options against traditionally hard-to-drug intracellular oncology targets (like KRAS) are being discovered at a more rapid pace and a few have even reached the market in the past few years. Not only do small molecules
As the industry increasingly shifts its attention to biologics, more attention is being paid to the prospect of developing biotherapeutics against membrane-bound targets. For these large target classes, biologics offer improved selectivity, an altern
A new generation of molecules are being developed to disrupt protein-protein interactions and to hijack the cell’s natural machinery for targeted protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other modalities are
Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets conference focuses on therapeutic candidates in clinical or earlier stage development that modulate molecules or cellular processes involved in neurodegenerative diseases, especial
26-28 September 2023
5th Annual RAS-Targeted Drug Development SummitPersonalizing Medicine Via Targeting Oncogenic RAS for CancerWith the approval of the second-ever KRAS G12C inhibitor, the field can once again celebrate irrevocable proof that RAS is druggable!
27-28 September 2023
Cambridge Healthtech Institute’s annual Lead Generation Strategies conference illuminates the latest approaches used by medicinal, biophysical and computational chemists to discover and develop small molecules (and now slightly larger molecules that
Fibrosis can be viewed as the end-stage of chronic inflammation. Fibrosis and inflammation are related to the immune system gone awry and both underlie many conditions related to aging and therefore are increasing in prevalence in the US. Cambridge H
Transcription factors are proteins with DNA-binding domains that are involved in gene transcription. They are key cell regulators and alterations in their structure, binding, or activity are often found associated with many abnormalities in cellular
30-02 November 2023
The 6th Targeted Protein Degradation Summit is the premier event for professionals in the field of protein degradation drug development. Returning to Boston in 2023, this summit has established itself as the longest-standing and most comprehensive ga